Juniper Biomedical has won Phase 3 of the NIH SPARC Neuromod Prize, earning a $1.6 million cash award that the company said will support ongoing product development and clinical trials for its lead therapy targeting mixed urinary incontinence (MUI).
The company said it previously won both the Phase 1 and Phase 2 Neuromod Prizes, bringing its total cash awarded through the program to $2.9 million. The Neuromod Prize is part of the National Institutes of Health’s SPARC initiative, which focuses on advancing neuromodulation science and accelerating next-generation therapies that target the peripheral nervous system.
Juniper is developing a neuromodulation micro-implant designed to deliver long-term precision therapy to pelvic nerves. The company’s initial focus is MUI, which combines stress urinary incontinence and urge urinary incontinence. Juniper said it aims to address an unmet need for less invasive, effective, and safe therapies for pelvic health disorders.
Separately, Juniper announced that medtech executive Frank Fischer has joined its board of directors. Fischer is the founder and chairman of NeuroPace and has led multiple medical device companies, including serving as president and CEO of NeuroPace from 2000 until July 2019. His prior roles also include president and CEO of Heartport and Ventritex, a pioneer in implantable cardiac defibrillators that was sold to St. Jude Medical in 1997.
Juniper said Fischer’s experience building medical device categories across cardiology and neurology will support its efforts to commercialize neuromodulation therapies for pelvic health.
KEY QUOTES:
“We are honored to welcome Frank Fischer to our Board of Directors. Frank’s extensive leadership experience and successful track record creating new medical device categories in cardiology and neurology will be invaluable to Juniper as we pioneer innovative neuromodulation therapies for pelvic health disorders. The Neuromod Prize has been a profound accelerant to the core translational effort required to bring Juniper’s innovation to the millions of patients suffering with inadequate solutions. Receiving this Phase 3 final award is a tremendous honor and a testament to the work of our deeply committed team.”
David Constantine, Co-Founder and CEO, Juniper Biomedical
“I’m pleased to join Juniper Biomedical’s Board of Directors. I’m impressed by the executive team and the company’s technology platform and am confident that Juniper has what it takes to bring to market its game-changing precision neuromodulation technology to address the unmet need for less invasive, effective, and safe therapies for pelvic health disorders.”
Frank Fischer, Board Member, Juniper Biomedical
